Abstract Library

#2938 Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report

Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Liu M, Chen L, Guo Y, Chen M,

Keywords: rectal neuroendocrine tumor, Erdheim-Chester disease.,

#2902 DNA Methylation Analysis of the PDX1 Gene Can Be Used for PNET Subtyping and Has a Possible Prognostic Value

Introduction: Estimating prognosis of pancreatic neuroendocrine tumor (PNET) patients remains challenging. Mutation status of DAXX/ATRX/MEN1, histone modification patterns and immunohistochemistry for relevant transcription factors, including PDX1, were recently used to perform subtyping and distinguished two main types, A and B. These subtypes are linked to cell-of-origin and associated with clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Boons G, Vandamme T, Ibrahim J, Schepers A, Roeyen G,

Keywords: Pancreatic Neuroendocrine Tumor, DNA Methylation, Prognostic Biomarker,

#2781 Case Report: Whole Exon Sequencing of Primary Lesion and Metastatic Liver Lesion in Pancreatic Neuroendocrine Tumor

Introduction: Pancreatic neuroendocrine neoplasms(NENs) are classified into neuroendocrine tumors (NET) G1, G2, G3, and neuroendocrine carcinoma (NEC), which are different pathogenesis. The two kinds of tumors that occurs in the same lesion in one patient is very rare. We found high grade neuroendocrine neoplasms(NENG3) with a diameter of 0.1 cm in a patient with a pancreatic NETG2 (1.7 cm in diameter). The cells were significant atypia with Ki67 index of 60%, focal necrosis, while metastatic nodules in the liver (12, 0.1-1.1 cm in diameter) were all high grade NENG3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shi Y, Zhong D, Li Y, Niu Y, Tan H,

Keywords: pancreatic neuroendocrine neoplasms, whole exon sequencing, TRIOBP signaling pathway, MDM4,

#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience

Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dureja S

Authors: Dureja S, Sen I, Pant V, Thak P,

Keywords: Targeted alpha therapy, TAT, PRRT, neuroendocrine tumors, beta refractory,

#2139 Genome-Wide DNA Methylation Profiling of Pancreatic Neuroendocrine Tumors

Introduction: Frequent inactivation of epigenetic regulators ATRX and DAXX in pancreatic neuroendocrine tumors (PNETs) suggests an important role for epigenetic alterations in tumorigenesis. Few studies have been published regarding differential methylation patterns in PNETs and a thorough analysis of these alterations is currently lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Boons G, Beyens M, Schepers A, Vandamme T, Roeyen G,

Keywords: pancreatic neuroendocrine tumor, DNA methylation,